Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune, Inc. (Nasdaq: ALT) announced its management team's participation in several upcoming virtual conferences. The Piper Sandler 33rd Annual Virtual Healthcare Conference will take place from November 29 to December 2, 2021. The 5th Annual NASH Summit 2021 is scheduled for November 30, 2021, at 9:00 am Eastern Time. Lastly, Altimmune will present at the 4th Annual Evercore ISI HealthCONx Conference on December 2, 2021, at 10:55 am Eastern Time. Presentation materials and webcasts are accessible on their website.
On November 10, 2021, Altimmune, a clinical-stage biopharmaceutical company listed on Nasdaq under the ticker ALT, announced upcoming presentations by its management team at two significant investor conferences.
- Stifel’s 2021 Virtual Healthcare Conference: November 15, 2021, at 10:40 am Eastern Time.
- Jefferies London Healthcare Conference: November 18, 2021, at 8:00 am GMT.
Both sessions will be accessible via the Altimmune website.
Altimmune, Inc. (Nasdaq: ALT) reported significant advancements in its pemvidutide program, showcasing a reduction of liver fat to undetectable levels in subjects with hepatic steatosis following a 6-week treatment. The company ended Q3 2021 with approximately $200 million in cash and short-term investments.
Financially, Altimmune's Q3 revenue was $0.2 million, down from $2.9 million in Q3 2020, with a net loss of $33.5 million. The firm is advancing its obesity program and is set to initiate Phase 2 trials in 2022.
Altimmune, Inc. (Nasdaq: ALT) has announced that it will report its third quarter 2021 financial results on November 10, 2021. The management team will host a conference call at 8:30 am E.T. to discuss these results and provide a business update. Investors can participate via domestic and international dial-in numbers or join a webcast available through their official site.
Altimmune focuses on developing treatments for obesity and liver diseases, with ongoing projects like ALT-801 for NASH and HepTcell™ for chronic hepatitis B.
Altimmune, a clinical-stage biopharmaceutical company, has announced that its management will present virtually at two upcoming H.C. Wainwright Investor Conferences. The presentations include the 5th Annual NASH Investor Conference on October 12, 2021 at 3:30 PM ET, and the Hepatitis B Virus Virtual Conference on October 13, 2021 at 4:30 PM ET. Interested individuals can access the sessions via the Events section on Altimmune's website.
Altimmune focuses on developing treatments for obesity and liver diseases, with key products including next-generation peptide therapeutics.
Altimmune has announced the enrollment of the first patient in a 12-week Phase 1b clinical trial for pemvidutide aimed at treating non-alcoholic fatty liver disease (NAFLD). Led by Dr. Stephen Harrison, the trial aims to include approximately 72 patients and is expected to read out topline data in the first half of 2022. Pemvidutide, a dual receptor agonist, has shown promising results in weight loss and metabolic health, with plans to initiate a Phase 2 NASH study based on the findings from this trial.
Altimmune, Inc. (Nasdaq: ALT) announced a Key Opinion Leader (KOL) call discussing its 12-week Phase 1 clinical trial of pemvidutide on September 30, 2021. The call will feature Dr. Stephen A. Harrison, an expert in non-alcoholic steatohepatitis (NASH), who will review safety and weight loss data. In the trial, subjects taking pemvidutide achieved significant weight losses of 4.9%, 10.3%, and 9.0% across different doses, whereas the placebo group lost only 1.6%. No serious adverse events were reported. Altimmune positions this treatment as crucial for addressing obesity and NASH.
Altimmune has reported promising results from a Phase 1 trial of its investigational drug, pemvidutide, intended for obesity and NASH treatment. Subjects receiving the 1.8 mg dose achieved a mean weight loss of 10.3% over 12 weeks, with no treatment discontinuations due to adverse events. The drug was well-tolerated, and the IND for NASH has cleared FDA review. Future clinical studies, including a 12-week NAFLD trial, are set to commence soon. Altimmune plans to initiate a 48-week Phase 2 obesity trial in H1 2022.
Altimmune, Inc. (Nasdaq: ALT) announced the upcoming results of its 12-week Phase 1 clinical trial for ALT-801, aimed at treating obesity, to be released on September 28, 2021. The company will provide details during a conference call and webcast at 8:30 AM ET, which will also be available for replay on its website. This trial represents a significant step in Altimmune's development pipeline focused on obesity and liver diseases, part of its broader strategy to advance next-generation therapeutics.
Altimmune, a clinical-stage biopharmaceutical company, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The presentation will be led by CEO Vipin Garg and CMO Scott Harris, with a pre-recorded session available on September 13 at 7 a.m. EST. Altimmune focuses on developing treatments for obesity and liver diseases, including therapies like ALT-801 for NASH and HepTcell™ for chronic hepatitis B. For further details, visit Altimmune's website.